Explore the vast range of titles available.

Highly charged heavy ions at rest offer a wide spectrum of precision measurements. The GSI Helmholtzzentrum für Schwerionenforschung GmbH is able to deliver ions up to U92+. As the production of these heavy, highly charged ions requires high kinetic energies, it is necessary to decelerate these ions for ultimate precision. The broad energy distribution, which results from the deceleration in the HITRAP linear decelerator, needs to be reduced to allow for further transportation and experiments. The HITRAP cooling trap is designed to cool, i.e., reduce, this energy spread by utilizing electron cooling. The commissioning of this trap is done with Ar16+-ions from a local EBIT ion source. By analyzing the signal of stored ions after ejection, properties such as ion lifetime, charge exchange, and ion motions can be observed. Here, we provide an overview of the recent results of the commissioning process and discuss future experiments.

Collinear laser spectroscopy in the 1s2s3S1→1s2p3P0,2 transitions of helium-like 11B3+ was performed using the HITRAP beamline at the GSI Helmholtz Centre. The ions were produced in an electron beam ion source, extracted, and accelerated to a beam energy of 4 keV/q. Results agree with previous measurements within uncertainty. Thus, it was demonstrated that the metastable state in He-like ions is sufficiently populated to carry out collinear laser spectroscopy. The measurement is a pilot experiment for a series of measurements that will be performed at a dedicated collinear laser spectroscopy setup at TU Darmstadt with light helium-like ions.

An improved moveable in vacuo XUV fluorescence detection system was employed for the laser cooling of bunched relativistic (β = 0.47) carbon ions at the Experimental Storage Ring (ESR) of GSI Helmholtzzentrum Darmstadt, Germany. Strongly Doppler boosted XUV fluorescence (∼90 nm) was emitted from the ions in a forward light cone after laser excitation of the 2s–2p transition (∼155 nm) by a new tunable pulsed UV laser system (257 nm). It was shown that the detected fluorescence strongly depends on the position of the detector around the bunched ion beam and on the delay (∼ns) between the ion bunches and the laser pulses. In addition, the fluorescence information could be directly combined with the revolution frequencies of the ions (and their longitudinal momentum spread), which were recorded using the Schottky resonator at the ESR. These fluorescence detection features are required for future laser cooling experiments at highly relativistic energies (up to γ∼ 13) and high intensities (up to 1011 particles) of ion beams in the new heavy ion synchrotron SIS100 at FAIR.

Quantum electrodynamics has been tested to accuracies below the parts-per-trillion level in light-mass systems. However, tests in heavy-mass systems with a large nuclear charge have not yet reached similar accuracy. Here we report the hyperfine-structure splitting in the 1 s ground state of radioactive hydrogen-like 208 Bi 82+ . We produced the isotope in a nuclear reaction and injected the beam into a storage ring to perform laser spectroscopy on samples of 10 5 ions of Bi 82+ that have only a single remaining electron, which experiences extreme magnetic-field strengths. Our result for the hyperfine splitting is in excellent agreement with the most accurate prediction based on a combination of quantum electrodynamics calculations with an empirical treatment of the hyperfine-structure anomaly ratio extracted from laser spectroscopy on neutral atoms of 209 Bi and 208 Bi. This achievement paves the way for the most stringent test of quantum electrodynamics in strong magnetic fields and demonstrates the feasibility of laser spectroscopy on other exotic ions with low production yields. Hyperfine splitting was measured using the laser spectroscopy of accelerator-produced hydrogen-like bismuth ions. This demonstrates the feasibility of such measurements with other exotic ions with low production yields in a storage ring.

We present the first measurements with a new collinear laser spectroscopy setup at the Argonne Tandem Linac Accelerator System utilizing its unique capability to deliver neutron-rich refractory metal isotopes produced by the spontaneous fission of 252Cf. We measured isotope shifts from optical spectra for nine radioactive ruthenium isotopes 106-114Ru, reaching deep into the mid-shell region. The extracted charge radii are in excellent agreement with predictions from the Brussels-Skyrme-on-a-Grid models that account for the triaxial deformation of nuclear ground states in this region. We show that triaxial deformation impacts charge radii in models that feature shell effects, in contrast to what could be concluded from a liquid drop analysis. This indicates that this exotic type of deformation should not be neglected in regions where it is known to occur, even if its presence cannot be unambiguously inferred through laser spectroscopy.

Inflammation plays a pivotal role in atherothrombosis. Colchicine is an anti-inflammatory drug that may attenuate this process. Cardiovascular protective effects of anti-inflammatory drugs, however, seem to be limited to patients with a biochemical response. We therefore investigated whether short-term exposure to colchicine reduced inflammatory markers and whether additional laboratory changes occur in patients with chronic coronary artery disease. In 138 consecutive patients with chronic coronary artery disease and a high sensitivity C-reactive Protein (hs-CRP) [greater than or equal to] 2 mg/L, inflammatory markers, lipids, haematologic parameters and renal function were measured at baseline and after 30 days exposure to colchicine 0.5mg once daily. Hs-CRP decreased from baseline 4.40 mg/L (interquartile range [IQR] 2.83-6.99 mg/L) to 2.33 mg/L (IQR 1.41-4.17, median of the differences -1.66 mg/L, 95% confidence interval [CI] -2.17 - -1.22 mg/L, p-value <0.01), corresponding to a median change from baseline of -40%. Interleukin-6 decreased from 2.51 ng/L (IQR 1.59-4.32 ng/L) to 2.22 ng/L (median of the differences -0.36 ng/L, 95%CI -0.70 - -0.01 ng/L, p-value 0.04), corresponding to a median change from baseline of -16%. No clinically relevant changes in lipid fractions were observed. Both leukocyte and thrombocyte count decreased (median change from baseline -7% and -4% respectively). Estimated glomerular filtration rate decreased with a mean change from baseline of -2%. In patients with chronic coronary artery disease and elevated hs-CRP, one-month exposure to colchicine 0.5 mg once daily was associated with a reduction of inflammatory markers. A small effect was seen on white blood cell count and platelet count, as well as a small decrease in estimated glomerular filtration rate.

Among adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, treatment with the bispecific anti-CD19 and anti-CD3 monoclonal antibody blinatumomab resulted in longer overall survival and higher remission rates than did chemotherapy. The prognosis for adults with newly diagnosed acute lymphoblastic leukemia (ALL) has improved over the past three decades. With the use of intensive chemotherapy regimens, complete remission rates are 85 to 90% and long-term survival rates are 30 to 50%. 1 – 4 Still, most adults with B-cell precursor ALL will have a relapse and will die from complications of resistant disease or associated treatment. Among adults with relapsed or refractory ALL, remission rates are 18 to 44% with the use of standard salvage chemotherapy, but the duration of remission is typically short. 5 – 10 A major goal in this population is to . . .

Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19, an antigen consistently expressed on B-lineage acute lymphoblastic leukaemia cells. We aimed to confirm the activity and safety profile of blinatumomab for acute lymphoblastic leukaemia. In a multicentre, single-arm, open-label phase 2 study, we enrolled adult patients with Philadelphia-chromosome-negative, primary refractory or relapsed (first relapse within 12 months of first remission, relapse within 12 months after allogeneic haemopoietic stem-cell transplantation [HSCT], or no response to or relapse after first salvage therapy or beyond) leukaemia. Patients received blinatumomab (9 μg/day for the first 7 days and 28 μg/day thereafter) by continuous intravenous infusion over 4 weeks every 6 weeks (up to five cycles), per protocol. The primary endpoint was complete remission (CR) or CR with partial haematological recovery of peripheral blood counts (CRh) within the first two cycles. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT01466179. Between Jan 13, 2012, and Oct 10, 2013, 189 patients were enrolled and treated with blinatumomab. After two cycles, 81 (43%, 95% CI 36–50) patients had achieved a CR or CRh: 63 (33%) patients had a CR and 18 (10%) patients had a CRh. 32 (40%) of patients who achieved CR/CRh underwent subsequent allogeneic HSCT. The most frequent grade 3 or worse adverse events were febrile neutropenia (48 patients, 25%), neutropenia (30 patients, 16%), and anaemia (27 patients, 14%). Three (2%) patients had grade 3 cytokine release syndrome. Neurologic events of worst grade 3 or 4 occurred in 20 (11%) and four (2%) patients, respectively. Three deaths (due to sepsis, Escherichia coli sepsis, and Candida infection) were thought to be treatment-related by the investigators. Single-agent blinatumomab showed antileukaemia activity in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia characterised by negative prognostic factors. Further assessment of blinatumomab treatment earlier in the course of the disease and in combination with other treatment approaches is warranted. Amgen.

Infection by the new corona virus strain SARS-CoV-2 and its related syndrome COVID-19 has been associated with more than two million deaths worldwide. Patients of higher age and with preexisting chronic health conditions are at an increased risk of fatal disease outcome. However, detailed information on causes of death and the contribution of pre-existing health conditions to death yet is missing, which can be reliably established by autopsy only. We performed full body autopsies on 26 patients that had died after SARS-CoV-2 infection and COVID-19 at the Charité University Hospital Berlin, Germany, or at associated teaching hospitals. We systematically evaluated causes of death and pre-existing health conditions. Additionally, clinical records and death certificates were evaluated. We report findings on causes of death and comorbidities of 26 decedents that had clinically presented with severe COVID-19. We found that septic shock and multi organ failure was the most common immediate cause of death, often due to suppurative pulmonary infection. Respiratory failure due to diffuse alveolar damage presented as immediate cause of death in fewer cases. Several comorbidities, such as hypertension, ischemic heart disease, and obesity were present in the vast majority of patients. Our findings reveal that causes of death were directly related to COVID-19 in the majority of decedents, while they appear not to be an immediate result of preexisting health conditions and comorbidities. We therefore suggest that the majority of patients had died of COVID-19 with only contributory implications of preexisting health conditions to the mechanism of death.